Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares Core MSCI EAFE ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while iShares Core MSCI EAFE ETF trades at $96.31. The key difference: iShares Core MSCI EAFE ETF is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | IEFA | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $28.06 | $98.56 |
52-Week Low | $20.06 | $81.70 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IEFA trades at $98.31, up 1.04% with a bullish technical signal from moving averages. The ETF focuses on developed international markets excluding North America, offering diversification from US concentration risks. Recent news highlights strong performance comparisons against peers like VXUS and EEM, with a competitive 3.30% dividend yield and low 0.07% expense ratio. Central bank policy shifts in Europe and Japan present both opportunities and headwinds for international exposure.
The outlook remains positive given technical momentum and diversification benefits, though currency fluctuations and developed market monetary policy changes pose risks. Analyst sentiment leans bullish with the ETF positioned as a core holding for international diversification, but investors should monitor geopolitical developments and relative performance against US equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
